drugset
drugset / Trial / NCT02365207

Intravesical BCG Administration to Patients With Invasive Bladder Cancer

NCT02365207 ↗

Terminated 6 enrolled The University of Texas Health Science Center at San Antonio
NaSingle-groupOpen-labelTreatment

Summary

Patients with invasive bladder cancer will be given 3-6 treatments (based on treatment response) BCG intravesically followed by a cystectomy.

Timeline

Start
2013-11
Primary completion
2018-09-30
Completion
2019-04-25

Outcome

Outcome not reported

Stopped (Enrollment): “Poor accrual of subjects and lack of funding”

Drugs

EvaluationDrugModalityDoseRoute
Subject BCG Tice Vaccine — —

Indications

urinary bladder cancer